Trending NewsTrending NewsNYSE:BMY Bristol Myers Squibb (BMY) Stock Price, News & Analysis $61.63 +0.02 (+0.03%) Closing price 03:59 PM EasternExtended Trading$61.90 +0.27 (+0.44%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bristol Myers Squibb Stock (NYSE:BMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bristol Myers Squibb alerts:Sign Up Key Stats Today's Range$60.92▼$61.6450-Day Range$56.73▼$68.0652-Week Range$42.52▼$68.64Volume7.78 million shsAverage Volume12.05 million shsMarket Capitalization$125.89 billionP/E Ratio13.57Dividend Yield4.09%Price Target$65.50Consensus RatingHold Company Overview Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas. The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches. Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R. Squibb in 1858. The two companies merged in 1989, creating Bristol-Myers Squibb. Today, the company serves patients and healthcare providers in the United States and international markets through a global network of research, manufacturing and commercial operations. Christopher Boerner has served as Bristol Myers Squibb’s chief executive officer since November 2023. The company is headquartered in Princeton, New Jersey, and works with researchers, healthcare professionals and other organizations to develop medicines intended to address significant unmet medical needs.AI Generated. May Contain Errors. Read More Bristol Myers Squibb Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreBMY MarketRank™: 4.56763035622 of 5 starsBristol Myers Squibb scored higher than 91% of companies evaluated by MarketBeat, and ranked 25th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.7 / 5Analyst RatingHold Consensus RatingBristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 2 strong buy ratings, 11 buy ratings, 16 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Bristol Myers Squibb is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBristol Myers Squibb has been the subject of 24 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bristol Myers Squibb's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth-0.15% Earnings GrowthEarnings for Bristol Myers Squibb are expected to decrease by -0.15% in the coming year, from $6.51 to $6.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bristol Myers Squibb is 13.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.08.Price to Earnings Ratio vs. SectorThe P/E ratio of Bristol Myers Squibb is 13.57, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.59.Price to Earnings Growth RatioBristol Myers Squibb has a PEG Ratio of 0.31. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBristol Myers Squibb has a P/B Ratio of 6.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bristol Myers Squibb's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.45% of the float of Bristol Myers Squibb has been sold short.Short Interest Ratio / Days to CoverBristol Myers Squibb has a short interest ratio ("days to cover") of 3.65, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bristol Myers Squibb has recently increased by 8.94%, indicating that investor sentiment is decreasing significantly. Dividend5.0 / 5Dividend StrengthStrong Dividend LeadershipBristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 4.10%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthBristol Myers Squibb has been increasing its dividend for 17 years.Dividend CoverageThe dividend payout ratio of Bristol Myers Squibb is 55.51%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 38.77% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.Read more about Bristol Myers Squibb's dividend. News and Social Media3.3 / 5News Sentiment0.28 News SentimentBristol Myers Squibb has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 63 news articles for Bristol Myers Squibb this week, compared to 9 articles on an average week.Search Interest51 people have searched for BMY on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows38 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 245% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bristol Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,750.00 in company stock.Percentage Held by Insiders0.05% of the stock of Bristol Myers Squibb is held by insiders.Percentage Held by Institutions76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bristol Myers Squibb's insider trading history. Receive BMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bristol Myers Squibb and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMY Stock News HeadlinesBristol Myers Squibb (BMY) Stock Fair Value Edges Lower On Split Analyst Views3 minutes ago | finance.yahoo.comBristol Myers Squibb (BMY) Stock Still Looks Reasonable Below Fair ValueOctober 27 at 2:59 PM | finance.yahoo.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.October 27 at 1:00 AM | Crypto 101 Media (Ad)What Does Bristol Myers Squibb (BMY) Zola Cel MS Trial Update Mean?October 27 at 4:57 AM | finance.yahoo.comBristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression — Here's Why It MattersOctober 27 at 2:13 AM | fool.com3 Cheap Dividend Stocks I'd Buy Without Any HesitationOctober 26 at 6:56 PM | fool.comBristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own StockBristol-Myers Squibb's iza-bren cut breast cancer progression risk by up to 38% in a Phase 3 trial, lifting shares and raising implications for rivals like Exelixis.October 26 at 1:50 PM | marketbeat.comBristol Myers Squibb: Bargain Buy or Value Trap?October 26 at 1:08 PM | fool.comSee More Headlines BMY Stock Analysis - Frequently Asked Questions How have BMY shares performed this year? Bristol Myers Squibb's stock was trading at $53.93 at the start of the year. Since then, BMY stock has increased by 14.3% and is now trading at $61.6270. How were Bristol Myers Squibb's earnings last quarter? Bristol Myers Squibb Company (NYSE:BMY) released its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.60 by $0.44. Bristol Myers Squibb's quarterly revenue was up 5.7% compared to the same quarter last year. Read the conference call transcript. When did Bristol Myers Squibb's stock split? Bristol Myers Squibb's stock split on Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were issued to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Bristol Myers Squibb have any subsidiaries? The following companies are subsidiaries of Bristol Myers Squibb: MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and others. Who are Bristol Myers Squibb's major shareholders? Bristol Myers Squibb's top institutional shareholders include Robeco Institutional Asset Management B.V. (0.35%), Artemis Investment Management LLP (0.14%), Fort Washington Investment Advisors Inc. OH (0.08%) and Douglas Lane & Associates LLC (0.07%). Insiders that own company stock include David V Elkins, Samit Hirawat, Christopher S Boerner, Theodore R Samuels II, Phil M Holzer, Benjamin Hickey and Bartie Wendy Short. View institutional ownership trends. How do I buy shares of Bristol Myers Squibb? Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bristol Myers Squibb own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include NVIDIA (NVDA), Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), Johnson & Johnson (JNJ), AT&T (T) and Verizon Communications (VZ). Company Calendar Record date for 8/3 Dividend7/02/2026Ex-Dividend for 8/3 Dividend7/02/2026Last Earnings7/30/2026Dividend Payable8/03/2026Record date for 11/2 Dividend10/02/2026Ex-Dividend for 11/2 Dividend10/02/2026Today10/27/2026Next Earnings (Estimated)10/29/2026Dividend Payable11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 13 days, BMY's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:BMY CIK14272 Webwww.bms.com Phone(609) 252-4621Fax212-546-4020Employees32,500Year Founded1887Price Target and Rating Average Price Target for Bristol Myers Squibb$65.50 High Price Target$78.00 Low Price Target$41.00 Potential Upside/Downside+6.3%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$4.54 Trailing P/E Ratio13.57 Forward P/E Ratio9.47 P/E Growth0.31Net Income$7.05 billion Net Margins18.87% Pretax Margin24.21% Return on Equity66.90% Return on Assets14.74% Debt Debt-to-Equity Ratio1.89 Current Ratio1.53 Quick Ratio1.38 Sales & Book Value Annual Sales$48.19 billion Price / Sales2.61 Cash Flow$8.15 per share Price / Cash Flow7.56 Book Value$9.09 per share Price / Book6.78Miscellaneous Outstanding Shares2,042,710,000Free Float2,041,694,000Market Cap$125.89 billion OptionableOptionable Beta0.19 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:BMY) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bristol Myers Squibb Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Bristol Myers Squibb With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
